Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2023-02-01 Transaction in Own Shar…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document is titled 'Transaction in Own Shares' and explicitly details the purchase of ordinary shares by PureTech Health PLC as part of its 'Share Buyback Programme'. It provides specific transaction dates, volumes, and prices. This directly corresponds to the definition of a 'Transaction in Own Shares' filing, which maps to the code POS (Report of the company buying back or selling its own shares (share repurchase/issuance)). The presence of the RNS Number and the structure suggest it is a regulatory disclosure, but the content is specifically about share repurchase activity.
2023-02-01 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Transaction in Own Shares' and explicitly details the purchase of ordinary shares by PureTech Health PLC as part of its 'Share Buyback Programme'. It provides specific transaction dates, volumes, and prices. This activity directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). This matches the definition for Transaction in Own Shares (Code: POS).
2023-01-31 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: "Transaction in Own Shares". It details the purchase of ordinary shares as part of a "Share Buyback Programme" on a specific date (27 January 2023), including volume, high, low, and VWAP prices. This directly corresponds to the definition of a Transaction in Own Shares report, which is classified as Code: POS (Transaction in Own Shares). The presence of the RNS Number (1662O) and the date (30 January 2023) confirms it is a regulatory disclosure related to share capital management.
2023-01-30 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title: "PureTech Health PLC Transaction in Own Shares". It details the purchase of ordinary shares as part of a "Share Buyback Programme" on a specific date (26 January 2023), including volume, highest, lowest, and VWAP prices. This activity directly corresponds to the definition of 'Transaction in Own Shares'. The filing code for this activity is POS.
2023-01-27 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of ordinary shares as part of a 'Share Buyback Programme'. It provides specific transaction dates, volumes, and prices, and concludes with the resulting number of shares in treasury and in issue. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it is distributed via RNS, the core content is a POS filing, not just an announcement of a report (RPA/RNS).
2023-01-25 English
AKLI Positive ADHD Pivotal Data in Kids 13-17 yrs
Regulatory Filings Classification · 99% confidence The document is dated January 6, 2023, carries an RNS Number (8686L), and begins with the standard header 'National Storage Mechanism'. It details clinical trial results (STARS-ADHD-Adolescents) for a subsidiary's product (EndeavorRx) and announces plans for an FDA label expansion filing in 2023. This structure—a brief announcement from a listed company regarding material, time-sensitive information, often referencing an attached or linked full announcement (in this case, Akili's announcement)—is characteristic of a general regulatory news service release. Since it is not a full Annual Report (10-K), a specific financial release (ER), or a proxy statement, the most appropriate classification for a general, time-sensitive regulatory disclosure distributed via RNS is 'Regulatory Filings' (RNS). The document length (17,474 chars) is substantial, but the format is that of a news wire announcement, not a comprehensive statutory report.
2023-01-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.